TrialAlzheimer's research & therapy2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Gerald Novak et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
56 papers cite it
this paperpooled ittrialcites it